NeoStem Selected to Present Panel Discussion on Stem Cell Therapy at New York Biotechnology Association 2010 Annual Meeting

USA - English

• USA - English

NEW YORK, April 15 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) (''NeoStem'' or the ''Company''), an international biopharmaceutical company with operations in the U.S. and China, announced that it has been selected to present a panel discussion at the New York Biotechnology Association (NYBA) 2010 Annual Meeting entitled "Adult Autologous Stem Cell Therapy vs. Allogeneic Stem Cell Therapy: Pros and Cons". The panel will be moderated by Alan Harris, M.D., Ph.D., NeoStem's Vice President of Regenerative Medicine, Drug Development and Regulatory Affairs.

The panel members will explore the differences between autologous (one's own) and allogeneic (donated) stem cell based therapies, including the application of adult autologous VSEL(TM) technology, which was co-invented by Mariusz Ratajczak, MD, Ph.D., head of the Stem Cell Biology Program at the James Graham Brown Cancer Center at the University of Louisville and exclusively licensed by NeoStem from the University of Louisville Research Foundation. Additional key topics for the panel discussion will include how stem cell therapies are used in the treatment of diseases, the regulatory considerations that govern the clinical development of different types of stem cells, their affect on the medical applications of stem cells and on the relevant business models for the commercialization of these therapies.

Robin Smith, M.D., NeoStem's Chairman and CEO, will be a member of the panel which will be held on Monday, April 19, 2010 at 2:15 p.m. EDT at the Marriott Marquis Hotel in New York City. Other participants on the panel will include Robert Hariri, M.D., Ph.D., Chief Executive Officer of Celgene Cellular Therapeutics, Sheldon A. Schaffer, Ph.D., Vice President of Corporate Development and Intellectual Property at Aastrom Bioseciences, Inc., and Neil Theise, M.D., Professor of Pathology and of Medicine at Albert Einstein School of Medicine/Beth Israel Medical Center. ''As a pioneer in the collection and storage of autologous adult stem cells, including very small embryonic-like stem cells, and a leader in the development of stem cell-based regenerative medicine, we are pleased that NYBA has selected NeoStem to present this panel and look forward to an informative exchange with the experts we have assembled on this very important topic of autologous and allogeneic stem cell therapy.'' said Dr. Smith.

Dr Smith has also been asked to present NeoStem at the Corporate showcase event taking place at the Annual Meeting at 11.30 am on Monday, April 19, 2010. She will discuss NeoStem's technology, the promise of adult stem cell therapy as well as potential partnership opportunities for those who may be attending the conference.

About NeoStem, Inc.

NeoStem, Inc. is engaged in the development of stem cell-based therapies and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSELTM technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com .

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the successful application of VSELTM technology and development of stem cell therapies, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward- looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010, as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

    For more information, please contact:

    NeoStem, Inc.
     Robin Smith, CEO
     Phone: +1-212-584-4174
     Email: [email protected]
     Web:   http://www.neostem.com

    CCG Investor Relations, Inc.
     Lei Huang, Account Manager
     Phone: +1-646-833-3417
     Email: [email protected]
     Web:   http://www.ccgirasia.com

     Crocker Coulson, President
     Phone: +1-646-213-1915
     Email: [email protected]

SOURCE NeoStem, Inc.